A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Frontiers in Pharmacology Année : 2024

A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis

Résumé

De novo purine nucleotide biosynthesis (DNPNB) consists of sequential reactions that are majorly conserved in living organisms. Several regulation events take place to maintain physiological concentrations of adenylate and guanylate nucleotides in cells and to fine-tune the production of purine nucleotides in response to changing cellular demands. Recent years have seen a renewed interest in the DNPNB enzymes, with some being highlighted as promising targets for therapeutic molecules. Herein, a review of two newly revealed modes of regulation of the DNPNB pathway has been carried out: i) the unprecedent allosteric regulation of one of the limiting enzymes of the pathway named inosine 5′-monophosphate dehydrogenase (IMPDH), and ii) the supramolecular assembly of DNPNB enzymes. Moreover, recent advances that revealed the therapeutic potential of DNPNB enzymes in bacteria could open the road for the pharmacological development of novel antibiotics.
Fichier principal
Vignette du fichier
fphar-15-1329011.pdf (3.98 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY - Paternité

Dates et versions

pasteur-04520637 , version 1 (25-03-2024)

Licence

Paternité

Identifiants

Citer

Nour Ayoub, Antoine Gedeon, Hélène Munier-Lehmann. A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis. Frontiers in Pharmacology, 2024, 15, pp.1329011. ⟨10.3389/fphar.2024.1329011⟩. ⟨pasteur-04520637⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More